Tech Company Financing Transactions
Attenua Funding Round
Omega Funds, Abingworth and OrbiMed invested in a $35 million Series A funding round for Attenua. The round was announced on 5/1/2018.
Transaction Overview
Company Name
Announced On
5/1/2018
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Proceeds Purpose
The new capital will be used to further develop Attenua's lead drug candidate ATA-101, which targets a new mechanism for chronic cough, in Phase 2 clinical trials, as well as to progress the company's pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
411 Borel Ave. 510
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Website
Email Address
Overview
Attenua is a clinical-stage biotechnology company developing novel medicines for the millions of patients who suffer from chronic respiratory disorders such as chronic cough.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Kitt
VP - Operations
Peter Butera
VP - Regulatory Affairs
Natalie McClure
Browse more venture capital transactions:
Prev: 5/1/2018: vSpatial venture capital transaction
Next: 5/1/2018: Datavant venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs